1. Home
  2. GAUZ vs APRE Comparison

GAUZ vs APRE Comparison

Compare GAUZ & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gauzy Ltd. Ordinary Shares

GAUZ

Gauzy Ltd. Ordinary Shares

HOLD

Current Price

$0.80

Market Cap

13.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAUZ
APRE
Founded
2009
2006
Country
Israel
United States
Employees
N/A
8
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6M
11.5M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
GAUZ
APRE
Price
$0.80
$0.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.50
$4.10
AVG Volume (30 Days)
560.7K
191.7K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.59
N/A
Revenue Next Year
$59.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.55
52 Week High
$9.60
$2.22

Technical Indicators

Market Signals
Indicator
GAUZ
APRE
Relative Strength Index (RSI) 56.18 43.25
Support Level $0.75 $0.75
Resistance Level $0.94 $0.81
Average True Range (ATR) 0.19 0.08
MACD 0.03 -0.01
Stochastic Oscillator 57.22 6.77

Price Performance

Historical Comparison
GAUZ
APRE

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: